-
Millions may be forced to move as climate change hits South Asia: UN
-
Chelsea captain James has knee surgery
-
Four killed battling Indonesia fires as toxic haze cloaks region
-
China tells Trump's press secretary to visit 'more often' after toilet comments
-
Thai farmers, fishermen challenge IMF, World Bank at Bangkok rally
-
'Under attack' from fragrance, Hanoi prunes its famous blossoms
-
In Malaysia, frustration grows over Indonesia haze
-
Families of children killed in Pakistan school roof collapse demand justice
-
Why India's voter revision drive has stoked fear and anger
-
Asian stocks rise as tech bounces from rout, Warsh upbeat on AI
-
Munster eye fitting tribute to 'special' Foley in Racing reunion
-
Trump's new press secretary says China lacked 'proper' toilets
-
Shooter kills teacher, three children at Oregon elementary school
-
India closes down New Delhi park ahead of 'cockroach' movement rally
-
Fed's Warsh surprised by world economy's 'resilience'
-
'Let us build': World Bank chief outlines jobs-led development agenda
-
Four killed in Indonesia battling fires causing toxic haze
-
Broncos top Super Bowl champion Seahawks in overtime
-
New Zealand star Ponga breaks arm in Rugby League World Cup opener
-
Brilliant Brewers sweep Dodgers to reach World Series
-
Indonesian stocks dive 11% as MSCI weighs market reclassification
-
Brewers complete Dodgers sweep to reach World Series
-
Seoul dismisses Pyongyang's scepticism over hypersonic weapon test
-
High-flying Freiburg try to shut out the noise as fairytale run continues
-
Yamal on song as entertainers Barcelona face Betis challenge
-
Flamengo secure 0-0 draw in La Plata in Copa Libertadores semi
-
Wong weighs haze prosecutions as Singapore air quality worsens
-
The final lap? Two days on the campaign trail with Trump
-
Brush fire prompts an evacuation order along Los Angeles coast
-
Asian stocks rise as tech bounces from rout, eyes on Warsh
-
'Mixed feelings': AI cracks centuries-old ciphers
-
Saudi organisers say 2027 Asian Cup 'on schedule' after attacks
-
Le Pen looms large as Macron enters final months on EU stage
-
Right-wing Brazil influencers on 'mission' to seal Bolsonaro win
-
Three children, one teacher killed in Oregon elementary school shooting
-
Using AI to help find Mexico's legions of missing children
-
Man Utd teetering towards crisis as Man City cloud hangs over Premier League
-
Fiji to deploy solar-powered Australian military drones at sea
-
Trump's new press secretary defends 'lawyer' title
-
Lawmakers Demand Menhaden Cuts Before Chesapeake Bay Science Is Complete, Ignoring Already Struggling Workers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 16
-
Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
-
'Multiple victims' in Oregon elementary school shooting, police say
-
Wallabies coach has 'faith' as All Blacks juggernaut awaits
-
'Multiple victims' in Oregon elementary school shooting: police
-
Ailing UK director Mike Leigh wishes he could make '100 more films'
-
ChangeNOW Announces NOW AI After Resolving Website Integration Vulnerability
-
Pixagram Announces Free Account Creation for 250 New Users Daily Through 2026
-
Argentine demonstration over education cuts ends in clashes
-
Macron warns urgent to strike EU budget deal before French vote runup
Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
M.King--AT